Vitex Acting On Inactine Viral Inactivation Technology Via Pentose Buy
This article was originally published in The Gray Sheet
Executive Summary
V.I. Technologies (Vitex) is putting aside its own red blood cell virus inactivation system development plans in favor of the Inactine technology-based red cell program of Pentose Pharmaceuticals via a definitive $45 mil. stock-swap merger deal announced July 28.